These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23137531)

  • 1. Cost-effectiveness of cardiovascular disease spending.
    Miller G; Cohen JT; Roehrig C
    J Am Coll Cardiol; 2012 Nov; 60(20):2123-4. PubMed ID: 23137531
    [No Abstract]   [Full Text] [Related]  

  • 2. Tradeoffs in cardiovascular disease prevention, treatment, and research.
    Miller G; Daly M; Roehrig C
    Health Care Manag Sci; 2013 Jun; 16(2):87-100. PubMed ID: 23090664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating Value Series.
    Ho PM
    Circ Cardiovasc Qual Outcomes; 2017 Jan; 10(1):. PubMed ID: 28093400
    [No Abstract]   [Full Text] [Related]  

  • 4. The cost effectiveness of cardiovascular medicines.
    Hay J
    Curr Atheroscler Rep; 2005 Mar; 7(2):79-80. PubMed ID: 15727719
    [No Abstract]   [Full Text] [Related]  

  • 5. [Economic effectiveness of prophylactic and therapeutic measures in cardiovascular diseases].
    Roĭtman MP; Lunskaia LL
    Sov Zdravookhr; 1982; (5):50-4. PubMed ID: 6808669
    [No Abstract]   [Full Text] [Related]  

  • 6. Transforming clinical trials in cardiovascular disease: mission critical for health and economic well-being.
    Antman EM; Harrington RA
    JAMA; 2012 Nov; 308(17):1743-4. PubMed ID: 23117771
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative effectiveness and health care spending--implications for reform.
    Weinstein MC; Skinner JA
    N Engl J Med; 2010 Feb; 362(5):460-5. PubMed ID: 20054039
    [No Abstract]   [Full Text] [Related]  

  • 8. Within trial cost-utility analysis of disease management program for patients hospitalized with atrial fibrillation: results from the SAFETY trial.
    Byrnes J; Ball J; Gao L; Kai Chan Y; Kularatna S; Stewart S; Scuffham PA
    J Med Econ; 2019 Sep; 22(9):945-952. PubMed ID: 31190590
    [No Abstract]   [Full Text] [Related]  

  • 9. Financial Hardship From Medical Bills Among Nonelderly U.S. Adults With Atherosclerotic Cardiovascular Disease.
    Valero-Elizondo J; Khera R; Saxena A; Grandhi GR; Virani SS; Butler J; Samad Z; Desai NR; Krumholz HM; Nasir K
    J Am Coll Cardiol; 2019 Feb; 73(6):727-732. PubMed ID: 30765039
    [No Abstract]   [Full Text] [Related]  

  • 10. Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study.
    Cobiac LJ; Magnus A; Barendregt JJ; Carter R; Vos T
    BMC Public Health; 2012 Jun; 12():398. PubMed ID: 22657090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. National spending on cardiovascular disease, 1996-2008.
    Miller G; Hughes-Cromwick P; Roehrig C
    J Am Coll Cardiol; 2011 Nov; 58(19):2017-9. PubMed ID: 22032718
    [No Abstract]   [Full Text] [Related]  

  • 12. QALYs in cost-effectiveness analysis: an overview for cardiologists.
    Wouters OJ; Naci H; Samani NJ
    Heart; 2015 Dec; 101(23):1868-73. PubMed ID: 26395316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost effectiveness of preventing cardiovascular diseases.
    Grover SA
    Can J Cardiol; 1999 Dec; 15 Suppl G():114G-6G. PubMed ID: 10692671
    [No Abstract]   [Full Text] [Related]  

  • 14. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. The value of cost-effectiveness analyses for reimbursement decisions: perspectives from Medicare.
    Sheingold SH
    Am Heart J; 1999 May; 137(5):S81-6. PubMed ID: 10220604
    [No Abstract]   [Full Text] [Related]  

  • 15. Identifying favorable-value cardiovascular health services.
    Braithwaite RS; Mentor SM
    Am J Manag Care; 2011 Jun; 17(6):431-8. PubMed ID: 21756013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review.
    Azari S; Rezapour A; Omidi N; Alipour V; Behzadifar M; Safari H; Tajdini M; Bragazzi NL
    Heart Fail Rev; 2020 Nov; 25(6):1077-1088. PubMed ID: 31832834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the costs and effectiveness of cardiovascular therapies: who cares about economic analyses?
    Califf RM
    Stat Med; 2002 Oct; 21(19):2889-97. PubMed ID: 12325105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiologist Participation in Accountable Care Organizations and Changes in Spending and Quality for Medicare Patients With Cardiovascular Disease.
    Sukul D; Ryan AM; Yan P; Markovitz A; Nallamothu BK; Lewis VA; Hollingsworth JM
    Circ Cardiovasc Qual Outcomes; 2019 Sep; 12(9):e005438. PubMed ID: 31522529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economics of Community Health Workers for Chronic Disease: Findings From Community Guide Systematic Reviews.
    Jacob V; Chattopadhyay SK; Hopkins DP; Reynolds JA; Xiong KZ; Jones CD; Rodriguez BJ; Proia KK; Pronk NP; Clymer JM; Goetzel RZ
    Am J Prev Med; 2019 Mar; 56(3):e95-e106. PubMed ID: 30777167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States.
    Boettiger DC; Newall AT; Phillips A; Bendavid E; Law MG; Ryom L; Reiss P; Mocroft A; Bonnet F; Weber R; El-Sadr W; d'Arminio Monforte A; de Wit S; Pradier C; Hatleberg CI; Lundgren J; Sabin C; Kahn JG; Kazi DS
    J Int AIDS Soc; 2021 Mar; 24(3):e25690. PubMed ID: 33749164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.